Theriva Biologics (NYSEAMERICAN:TOVX) Trading 3.4% Higher – Still a Buy?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s share price rose 3.4% during mid-day trading on Tuesday . The stock traded as high as $0.2450 and last traded at $0.2388. Approximately 1,538,827 shares were traded during mid-day trading, a decline of 67% from the average daily volume of 4,710,868 shares. The stock had previously closed at $0.2309.

Theriva Biologics Stock Performance

The stock has a market capitalization of $2.29 million, a PE ratio of -0.01 and a beta of 0.65. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.19 and a current ratio of 1.19. The firm has a 50 day moving average of $0.36 and a 200-day moving average of $0.42.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its earnings results on Wednesday, November 12th. The company reported ($0.45) earnings per share for the quarter.

Institutional Investors Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP bought a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned 0.64% of Theriva Biologics as of its most recent SEC filing. 6.17% of the stock is owned by hedge funds and other institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.